The AACR Call to Action
Cancer Progress Report 2016: Contents
Late last year, as the FY 2016 appropriations bill was being finalized, a bipartisan majority of members of Congress called for a significant funding increase for the NIH. The result was a $2 billion budget increase for the NIH in FY 2016, the agency’s first significant annual funding boost in more than a decade.
During Senate debate on this year’s (FY 2017) appropriations bill that provides funding to the NIH, Senator Roy Blunt (R-MO), Chairman of the Senate Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies, stated, “Last year, I made clear that sustained funding was as important as the increased investment. A pattern begins in the second year, and we have seized the opportunity this year to begin a pattern of increases for the NIH.” Chairman Blunt backed up his words by proposing another $2 billion funding increase for the NIH in FY 2017.
The AACR is supportive of Senator Blunt’s statement and action in his role as Subcommittee Chairman, especially because of the unprecedented scientific opportunities that exist today to improve the way we prevent, detect, diagnose, and treat cancer. Robust, sustained, and predictable investments in biomedical research, coupled with comparable funding increases for the FDA, will accelerate progress against cancer at this critical time in the cancer field.
The AACR also applauds Vice President Joe Biden’s comprehensive proposal for preventing cancer and accelerating the discovery of new cancer treatments through the National Cancer Moonshot Initiative. This timely initiative has galvanized the cancer community and sparked a renewed dialogue on how we can speed the pace of progress for the benefit of all patients with cancer. Working together, we can capitalize on this unique moment in cancer research to harness the extraordinary knowledge obtained through past federal investments, and allow for the translation of this information into strategies to prevent, detect, diagnose, and treat cancer.
Therefore, the AACR respectfully urges Congress and the Administration to:
Support the Senate Appropriations Labor, Health and Human Services, Education, and Related Agencies Subcommittee’s FY 2017 bill, which proposes to provide an increase of $2 billion for the NIH in FY 2017.
Finalize a Senate version of the House-passed 21st Century Cures Act that includes crucial funding for the NIH to support the National Cancer Moonshot Initiative and other important strategic research initiatives.
Support an FDA budget in FY 2017 of $2.85 billion, $120 million above its FY 2016 level, to ensure support for regulatory science and the timely approval of therapeutics that are safe and effective.
Readjust the discretionary budget caps for FY 2018 and beyond, which would allow our nation’s policymakers to continue to provide robust, sustained, and predictable funding increases for the NIH, NCI, and FDA in future years.
By taking such actions, we will improve our nation’s health, sustain our leadership in cancer research and biomedical science, and spur our innovation-based economy.
Top of page
Progress Report 2016 Contents